Losartan and Longevity: Can a Common Blood Pressure Drug Turn Back the Aging Clock?

 

A 2026 study published in Aging Cell by researchers from Johns Hopkins University and the National Institute on Aging provides compelling support for this concept. Using a multi-omics approach, simultaneously analyzing metabolites and proteins across biological systems, the investigators demonstrated that losartan shifts molecular profiles in both aged mice and elderly men toward a more youthful state. While this does not represent a reversal of aging, it highlights a meaningful modulation of age-associated biochemical pathways.

The Science Behind Losartan’s Surprising Effects on the Aging Metabolome

There is a widely prescribed drug, found in millions of medicine cabinets, primarily used to treat high blood pressure. This drug, losartan, is inexpensive, well-characterized, and has been safely used for decades. However, emerging evidence suggests that its biological impact may extend far beyond cardiovascular regulation. Recent research indicates that losartan may partially reverse molecular signatures associated with aging.

What Is the Aging Metabolome, and Why Does It Matter?

The metabolome represents the complete set of small molecules—metabolites—present within a biological system at a given time. These molecules arise from cellular processes such as energy production, biosynthesis, and signaling. As such, the metabolome serves as a real-time functional readout of cellular physiology.

With aging, the metabolome undergoes systematic alterations. Certain metabolites decline, others accumulate, and overall metabolic balance shifts. These changes reflect disruptions in core biological processes, including energy metabolism, lipid regulation, and cellular maintenance pathways. Understanding these shifts provides a framework for identifying interventions that may restore youthful metabolic states.

Losartan, unexpectedly, appears to influence this system.

The Renin-Angiotensin System: More Than Just Blood Pressure

Losartan functions as an angiotensin receptor blocker (ARB), targeting the renin-angiotensin-aldosterone system (RAAS), a central regulator of blood pressure and fluid homeostasis. Specifically, it inhibits the angiotensin II type 1 receptor (AT1R), preventing vasoconstriction and fluid retention.

Beyond its classical role, the RAAS has been increasingly linked to aging biology. Notably, genetic deletion of AT1R in mice has been shown to extend lifespan by approximately 26%. In humans, variants in the same pathway are enriched in centenarian populations. These observations suggest that modulation of RAAS signaling may influence longevity.

This raises a critical question: can pharmacological inhibition of AT1R using losartan replicate these longevity-associated effects?

The Experiment: Two Species, One Drug, Many Molecules

To address this, researchers conducted a comprehensive study across both murine and human systems. In mice, young (4 months) and aged (24–28 months) cohorts were analyzed alongside genetically modified animals lacking AT1R or AT2R receptors. A subset of aged mice received losartan treatment for four weeks.

Metabolomic profiling of serum assessed 122 metabolites, while proteomic analysis of cardiac tissue quantified over 1,200 proteins.

In parallel, human data were obtained from a phase 2 clinical trial involving pre-frail elderly men (≥70 years), treated with escalating doses of losartan (25 mg, 50 mg, 100 mg). Longitudinal blood samples enabled evaluation of dose-dependent metabolic effects.

This dual-species, multi-layered design allowed for direct comparison of aging signatures and drug responses.

The Findings in Mice: A Molecular Rejuvenation

Aged mice exhibited a consistent decline in key metabolites, including carnitine, ornithine, spermidine, and multiple lipid species such as lysophosphatidylcholines and sphingomyelins. Importantly, aging was characterized primarily by loss rather than accumulation of metabolites.

Losartan treatment reversed many of these changes. Levels of carnitine, phosphatidylcholines, and sphingomyelins increased toward youthful levels. Statistical analysis confirmed a significant inverse relationship between aging effects and losartan-induced changes, indicating that the drug systematically counteracts age-associated metabolic decline.

In essence, losartan shifts the metabolomic profile of aged mice toward a younger state.

The Role of the Receptors

Receptor knockout models revealed important mechanistic insights. Both AT1R-deficient and AT2R-deficient mice displayed partially rejuvenated metabolomic profiles even in the absence of drug treatment.

However, losartan’s effects were diminished in AT1R knockout mice and paradoxically reversed in AT2R knockout mice. These findings indicate that the drug’s full activity requires functional interaction between both receptor pathways. Rather than acting solely through AT1R blockade, losartan appears to depend on signaling between AT1R and AT2R.

Beyond the Blood: The Heart’s Proteome

Proteomic analysis of cardiac tissue revealed extensive remodeling with aging, with 247 proteins significantly altered. Losartan opposed these changes, showing a strong inverse correlation with age-related protein shifts.

The most prominent pathway affected was oxidative phosphorylation (OXPHOS), a key mitochondrial energy-generating process. Aging increased OXPHOS protein abundance, potentially as a compensatory response to declining mitochondrial efficiency. Losartan reversed this trend, restoring a more youthful proteomic pattern.

This suggests that losartan may influence mitochondrial biology, potentially reducing mitochondrial burden or improving efficiency at the cellular

Survival: The Hardest Test

To assess functional relevance, researchers evaluated survival in extremely aged mice (~30 months). After a short four-week treatment, losartan improved survival over a two-month observation period.

Despite limitations in study duration, this result demonstrates that even late-life intervention can produce measurable benefits in lifespan outcomes.

Translating to Humans: The Clinical Trial Data

In elderly men, losartan also shifted the metabolome in a direction opposite to aging. At 25 mg, this effect was statistically significant, with maximal impact observed at 50 mg.

Key lipid classes, including phosphatidylcholines and sphingomyelins, were again central to these changes, supporting cross-species consistency.

The Species Paradox: Same Drug, Mirror-Image Effects

A notable finding was that aging affects metabolite levels in opposite directions across species. In mice, metabolite levels decline with age, whereas in humans, they tend to increase.

Losartan mirrors these patterns: it raises metabolite levels in mice but lowers them in humans. In both cases, however, the drug moves the metabolome toward a youthful baseline.

This paradox is likely explained by differences in plasma volume dynamics. Aging reduces plasma volume in humans (concentrating metabolites) but increases it in mice (diluting metabolites).

Limitations and What Comes Next

Several limitations must be considered. The mouse studies included only males, and human sample sizes were small. The survival study was not a full lifespan analysis, and treatment duration was limited.

Mechanistically, the precise pathways remain unclear. Potential contributors include fluid regulation, mitochondrial remodeling, and direct receptor-mediated signaling. These mechanisms are likely interconnected and require further investigation.

Clinically, losartan is not universally suitable and carries risks such as altered kidney function and electrolyte imbalance. Additionally, the observed dose-response highlights the importance of optimal dosing.

The Bigger Picture

This study stands out due to its integrative approach, combining metabolomics, proteomics, animal models, and human clinical data. The convergence of evidence across these layers strengthens the conclusion that losartan modulates aging-associated biology.

It also builds upon decades of research linking RAAS signaling to longevity. From genetic studies to pharmacological interventions, the pathway consistently emerges as a regulator of aging processes.

Losartan is not an anti-aging cure. However, it represents a well-established, accessible drug with growing evidence for broader biological effects. Importantly, this work exemplifies rigorous, translational science—moving beyond speculation toward measurable, reproducible outcomes.

The trajectory is clear: aging may not be fully reversible, but it is increasingly modifiable at the molecular level.

Reference

Based on: Bene et al. “Multi-Omics Reveals Mechanisms of Metabolic Rejuvenation in Aged Mice and Pre-Frail Older Men by Losartan.” Aging Cell, 2026; 25:e70498

Image credit: Portions of the figure in this article were generated using ChatGPT (OpenAI) or Google Gemini.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)